GenEditBio is a clinical-stage biotech company based in Hong Kong, focused on developing in vivo gene editing medicines, or “affordable precision DNA surgery”, for genetic diseases with unmet needs. Our approach simplifies manufacturing and lowers costs, making advanced therapies more affordable and accessible. We are a platform-based company with programs currently spanning ophthalmology (GEB-101 for TGFBI corneal dystrophy), oncology (in vivo CAR-T) and cardiometabolic diseases (GEB-200 for high Lp(a) atherosclerotic cardiovascular disease). The programs are supported by our tech platform, comprised of three core capabilities: targeted delivery through Protein Delivery Vehicle (PDV), precise gene editing by novel Lead Editor (LE), and sensitive off-target detection with EDITED-Seq.

My Sourcing

GenEditBio Limited

Company Information

Contact